glp 1 dpp 4 DPP4 Inhibitors vs GLP-1 Agonists | June 2021 | Clinical Corner DPP-4 inhibitors and GLP-1RAs: cardiovascular
Description
What happens to that money depends entirely on the contract structure
Tell your doctor about all drugs and supplements you take to avoid issues
Your hydration may need to be more intentional
It works best as part of a comprehensive plan including compression, lymphatic massage, and medical monitoring
Discontinuation and Duration Dependent Cardiovascular Risk Compared with continual use of GLP-1s, discontinuing treatment for 6 months was associated with a 4% increased risk of major adverse cardiovascular events
Overall, when added to metformin therapy, sitagliptin significantly lowered 24-hour weighted mean glucose, thereby improving 24-hour glycemic control
